US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

The trial, which was funded by the drugs’ maker Eli Lilly, found that most patients on the medication had their blood sugar .

Patients treated with Wegovy had a higher risk of hip and pelvic fractures than placebo recipients ... GIPR is involved in insulin release and glycemic control. Rival drugs from Eli Lilly and Viking ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

The move comes despite last week's update when the FDA revised its shortage list to note that the .25 mg starter dose of ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...